David R. Margrave's most recent trade in Lantern Pharma Inc was a trade of 20,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Dec. 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lantern Pharma Inc | David R. Margrave | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2025 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Lantern Pharma Inc | David R. Margrave | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 Sep 2025 | 78,300 | 0 | - | - | Stock Option (Right to Buy) | |
| Lantern Pharma Inc | David R. Margrave | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Sep 2025 | 78,300 | 78,300 | - | - | Stock Option (Right to Buy) | |
| Lantern Pharma Inc | David R. Margrave | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 Sep 2025 | 26,100 | 0 | - | - | Stock Option (Right to Buy) | |
| Lantern Pharma Inc | David R. Margrave | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Sep 2025 | 26,100 | 26,100 | - | - | Stock Option (Right to Buy) | |
| Lantern Pharma Inc | David R. Margrave | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2024 | 52,000 | 52,000 | - | - | Stock Option (Right to Buy) | |
| Lantern Pharma Inc | David R. Margrave | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2021 | 26,100 | 26,100 | - | - | Stock Option (Right to Buy) |